benzyl 2(RS)-[[(RS)-(ethoxy)[(2,5-dioxo-1-imidazolidinyl)methyl]phosphinyl]methyl]-4-methylvalerate → 2(RS)-[[(RS)-(ethoxy)[(2,5-dioxo-1-imidazolidinyl)-methyl]phosphinyl]methyl]-4-methylvaleric acid
反応式
[CH2:1]([O:3][P:4]([CH2:14][CH:15]([CH2:26][CH:27]([CH3:29])[CH3:28])[C:16]([O:18]CC1C=CC=CC=1)=[O:17])([CH2:6][N:7]1[C:11](=[O:12])[CH2:10][NH:9][C:8]1=[O:13])=[O:5])[CH3:2]>C(O)C.[Pd]>[CH2:1]([O:3][P:4]([CH2:14][CH:15]([CH2:26][CH:27]([CH3:28])[CH3:29])[C:16]([OH:18])=[O:17])([CH2:6][N:7]1[C:11](=[O:12])[CH2:10][NH:9][C:8]1=[O:13])=[O:5])[CH3:2]参加物
4
実験手順
0.27 g 0.64 mmol) of benzyl 2(RS)-[[(RS)-(ethoxy)[(2,5-dioxo-1-imidazolidinyl)methyl]phosphinyl]methyl]-4-methylvalerate was dissolved in 10 ml of ethanol and the solution was hydrogenated in the presence of 0.2 g of 10% palladium/carbon at room temperature and under atmospheric pressure. After 1 hours, the catalyst was removed by filtration and the solvent was evaporated to give 0.22 g of 2(RS)-[[(RS)-(ethoxy)[(2,5-dioxo-1-imidazolidinyl)-methyl]phosphinyl]methyl]-4-methylvaleric acid in the form of a foam;